KKKairat Kabulbayev

Kairat Kabulbayev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kairat Kabulbayev has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • IgA Nephropathy: Current Treatment Strategies and Perspectives on Targeted Therapy

    by Gulnar Chingayeva, Dina Karibayeva, Assel Issenova, Abay Shepetov, Nagima Mustapayeva, Nazym Nigmatullina, Kairat Kabylbayev, Elmira Alimzhanova, Marzhan Shepetova, Zhadira Abiyeva, et al.

    Background: Immunoglobulin A nephropathy is among the most commonly observed glomerular disorders. Its development is associated with immune dysfunction, which initiates a cascade of pathological changes within the glomeruli. The clinical course can range from minimal urinary abnormalities to progressive renal impairment, potentially culminating in end-stage kidney disease. Despite considerable advances in understanding its pathogenesis, optimal therapeutic strategies remain an active focus of scientific investigation. Aim: To assess current and emerging therapeutic strategies for IgA nephropathy, with an emphasis on efficacy, safety, and the potential of targeted agents addressing key pathogenic pathways. Methods: We conducted a narrative review of recent literature in PubMed, Scopus, Web of Science, and eLIBRARY databases, focusing on publications from the last decade. Studies published in English and Russian that reported results from clinical trials or meta-analyses on therapeutic interventions for IgA nephropathy were included. Search terms included «IgA nephropathy», «treatment», «targeted therapy», «new therapies», «immunosuppressants», and «clinical trials». Priority was given to randomized controlled trials and studies with high-quality evidence, though relevant observational data were also considered. Results: Key studies identified included 52 publications, among which 20 were randomized clinical trials and a systematic review. Corticosteroid therapy remains a cornerstone of treatment but is limited by significant adverse effects. Recent therapeutic developments in IgA nephropathy have focused on interventions that selectively target inflammatory and immune pathways involved in disease progression. Certain novel agents aimed at modulating immune signaling or addressing pathogenic plasma cells have shown potential to reduce proteinuria and stabilize renal function. Early-phase clinical investigations indicate promising efficacy and manageable safety profiles, suggesting these approaches may represent important advances in disease management. Conclusions: Recent progress in targeted and immunomodulatory therapies offers new perspectives for personalized treatment of IgA nephropathy. Comprehensive, large-scale randomized studies with extended follow-up are warranted to thoroughly assess the therapeutic potential, safety profile, and optimal positioning of these interventions within future clinical management strategies.

  • Integrating Novel Complement Inhibitors into Clinical Practice: A National Call to Action for C3 Glomerulopathy and IgA Nephropathy in Kazakhstan

    by Saltanat Tuganbekova, Gulzhan Yertlessova, Kairat Kabulbayev, Ainur Botabayeva, Duman Turebekov, Aigul Karabayeva, Sholpan Kanafina, Galiya Shaimardanova, Olimkhon Sharapov, Fariz Babayev, et al.

    The advent of targeted complement inhibitors represents a paradigm shift in managing complement-mediated nephropathies. Integrating these therapies into healthcare systems, particularly in resource-variable settings, requires strategic planning. A national council of experts was convened in October 2024 with the purpose of obtaining a clinical expert opinion to develop practical recommendations for improving the organization and optimization of medical care for patients with C3 glomerulopathy (C3G) and IgA nephropathy (IgAN) in Kazakhstan. The council identified critical systemic gaps, including inconsistent use of renal biopsy, lack of specialized nephropathology, absence of treatment algorithms, and fragmented patient care. A consensus was reached on key recommendations for a new national clinical protocol. These include mandating pathological confirmation, creating detailed treatment and monitoring algorithms, establishing a national registry and coordination center, and investing in specialized training for healthcare professionals. The systematic framework proposed by the council provides an actionable roadmap to overcome barriers to care. This model ensures equitable patient access to novel therapies and may serve as a blueprint for other nations navigating the integration of advanced treatments into clinical practice.

  • Open Access

    Characteristics of Hepatitis B and C Infections in Hemodialysis Patients in Almaty, Kazakhstan's Largest City.

    by Arina Yespotayeva, Kairat Kabulbayev, Almagul Kurmanova, Alexander V. Nersesov, Aigul Raissova, Venera Ayupova, Meruyert Suleimenova, Nagima Mustapayeva, Aisulu Gainutdin

    Background and aims: Chronic viral hepatitis, including Hepatitis B (HBV) and Hepatitis C (HCV), remains a major health concern among hemodialysis patients. This study analyzes the prevalence and characteristics of HBV and HCV infections in hemodialysis patients treated at a single center in Almaty, focusing on comorbidities such as diabetes, hypertension, and cirrhosis. This study aims to determine the prevalence of these infections among hemodialysis patients in Kazakhstan and assess their associated comorbidities, complications, and overall impact on patient health. Methods: Data from the Almaty Center of Hepatology (2016–2023) served as the basis for the study cohort. Inclusion criteria included CKD stage 5, hemodialysis dependence, ESRD, and confirmed HBV, HCV, or both. The study consists of 164 patients diagnosed with HBV, HCV, or mixed infections, with data collected on demographic distribution, viral genotype prevalence, fibrosis staging, and associated conditions. Results: The findings highlight a substantial prevalence of comorbid conditions in hemodialysis patients with viral hepatitis. The study population includes 95 males (57.9%) and 69 females (42,1%), with a slight male predominance. HCV was the most common infection (76.8%), followed by HBV (14%) and mixed HCV+HBV (9.2%). The high percentage of an unspecified genotype (36.4%) suggests that enhanced diagnostic strategies are needed. Cirrhosis was observed in nearly 90% of the cohort, and 92.7% exhibited ascites. Fibrosis progression was significant, with 25.5% of patients in stage 1, 24.2% in stage 2, and 18.8% in stage 3. The prevalence of hypertension (53.9% with high-risk stage 3 hypertension), diabetes (14.5% with type 2 diabetes), and cirrhosis (89.7%) was assessed. Additionally, hepatitis genotypes were identified, with HCV genotype three being the most common (18.2%) and genotype 1 (17.6%). Conclusions: The results of this study demonstrate that patients on hemodialysis with viral hepatitis represent a particularly vulnerable group with a high incidence of severe liver damage and multiple comorbidities. The high rates of advanced fibrosis, cirrhosis, and associated conditions such as hypertension and diabetes underscore the need for timely diagnosis and complex, patient-centered care

  • Fibroblast growth factor 23 (FGF-23) and chronic kidney disease in children

    by Altynay Balmukhanova, Kairat Kabulbayev, Assiya Kanatbayeva

    Chronic kidney disease (CKD) in children is a complex medical and social problem in healthcare. One of the serious complications is mineral bone disorder (MBD), the pathogenesis of which is related to a new biomarker of bone origin - fibroblast growth factor 23 (FGF-23). The aim. To study the features of fibroblast growth factor 23 (FGF-23) in children with chronic kidney disease. Material and methods. A cross-sectional study was carried out on 73 children with CKD and 14 healthy children. Inclusion criteria: chronic kidney disease stage 1-5, written informed consent of the participants. The exclusion criteria: tubulopathy, infectious and inflammatory processes, oncological diseases, kidney transplant, condition after surgery, taking glucocorticosteroids, calcium and vitamin D drugs. We took fasting blood samples of participants and carried out an enzyme-linked immunosorbent assay in order determine the level of FGF-23 (Biomedica Medizinprodukte GmbH, Austria). The obtained data were analyzed using IBM SPSS, version 22 (New York, USA). Results and discussion. In healthy children, the median (Q1-Q3) level of FGF-23 in serum was 0.65 (0.22-0.98) pmol/l, in patients with stage 1 CKD it was 0.65 (0.22-1.08) pmol/l. At stage 2, the level of FGF-23 significantly increased in comparison with healthy individuals and with patients of stage 1, p≤0.05. Further, there is a gradual increase by stages, p≤0.05. Thus, in stage 3 patients, the median FGF-23 value was 1.9 (1.15-3.5) pmol/l, at stage 4 - 3.55 (2.48-6.35) pmol/l, at 5 stages - 14 (7.5-18.75) pmol/l. As a percentage, there were 7.1% of patients at the stage 1 with increased levels of phosphatonin, at stage 2 - 53.3%, at stage 3 - 69.2%, respectively. At stages 4 and 5, absolutely 100% of patients had high levels of FGF-23. At the same time, FGF-23 did not depend on gender, age, birth weight and type of renal replacement therapy at stage 5, p>0.05. Conclusions. Thus, in our study, we determined the features of changes FGF-23 in serum in children at various stages of CKD. The obtained results allow us to consider FGF-23 as a predictor of the clinical course of CKD. Keywords: fibroblast growth factor 23, phosphatonin, pediatric nephrology, chronic kidney disease, mineral-bone disorder.

  • The significance of Fibroblast growth factor 23 (FGF-23) in humans

    by Altynay Balmukhanova, Assiya Kanatbayeva, Kairat Kabulbayev, Maxsot Karasayev, Dinara Batyrbayeva

    Nowadays chronic kidney disease (CKD) is one of the leading chronic non-communicable diseases in terms of morbidity and mortality. One of the most serious complications is mineral-bone disorder, which worsen the clinical course and prognosis of patients. Fibroblast growth factor 23 (FGF-23) is a new biomarker that regulates phosphate metabolism and plays an important role in the pathogenesis of many complications in CKD. Purpose. To study the physiological role of FGF-23, as well as its potential clinical significance in the progression of CKD and its complications. Material and methods. A 20-year-deep literature search was conducted in the international scientific databases PubMed / Medline, Web of Science and Google Scholar for the following keywords: "Fibroblast growth factor 23", "FGF-23", "phosphate homeostasis", "chronic kidney disease", "Mineral and bone disorders", "left ventricular hypertrophy". Results and discussion. FGF-23 is a protein secreted by bone cells and its primary physiological role is to regulate urinary excretion of phosphate to maintain a stable level in serum. Moreover, FGF-23 decreases calcitriol levels and inhibits parathyroid hormone secretion. In CKD, there is a gradual increase in FGF-23 levels as renal function declines, which can be regarded as physiological compensation to stabilize serum phosphate levels. According to the several studies, FGF-23 might be associated with cardiovascular complications, such as left ventricular hypertrophy and heart failure. Conclusion. Thus, FGF-23 is not only a marker of mineral-bone disorders in CKD, but also a key link in the pathogenesis of the development of secondary hyperparathyroidism and cardiovascular complications. With this in mind, FGF-23 may represent a multifunctional therapeutic target that may improve the prognosis of patients with CKD. Keywords: fibroblast growth factor-23, phosphate, parathyroid hormone, left ventricular hypertrophy, mineral-bone disorder.


  • P1489HEPATITIS B AND C IN DIALYSIS UNITS IN ALMATY

    by Arina Yespotayeva, Kairat Kabulbayev, Abduzhappar Gaipov, Zauresh Amreyeva, Zhanar Mursalova

    Background and Aims: Patients getting maintenance haemodialysis (HD) are at higher risk for acquiring Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infections than the general population. Strict infection control measures are essential to prevent nosocomial transmission. We aimed to investigate the incidence and prevalence of HBV and HCV infection in the HD population of Almaty dialysis units as well as risk factors for infection. Method: All adult patients getting maintenance HD (n=700) in Almaty dialysis centres (n=4) were studied between May 2016 and December 2019. Testing for Hepatitis B surface antigen (HBsAg) and anti-HCV antibodies was performed at initiation of dialysis and every 3–6 months thereafter. Serological markers for HBV and HCV were determined with immunoenzymatic assay (ELISA). Results: Participant median age was 40 years and 58% were male. 110 patients (34.9%) were sero-positive for HBV and/or HCV (anti-HCV positive 31.1%; HBsAg positive 2.6%; both positive 1.2%). Of the sero-positive patients 4.7% were known to be infected before the initiation of HD. The prevalence of HBV±HCV infection varied widely between HD centres from 0% to 75.9%. Sero-positive patients were younger, had longer time on dialysis and more previous blood transfusions. Wide variation in rates of newly acquired infections was observed between dialysis centres. All new HBV cases were referred from centres already treating HBV infected patients. New HCV infections were reported in most centres but the rate of HCV sero-conversion varied widely from 1.5% to 31%. Duration of dialysis, history of previous renal transplant and history of receiving HD in another centre in Almaty were significantly associated with sero-conversion. Major risk factors identified by a standard questionnaire in 302 of 270 patients were the number of blood transfusions individuals had received and duration of dialysis, the latter including patients who received no blood transfusions Conclusion: HBV and HCV prevalence in our HD patients is still high. These data emphasize the need for stricter adherence to infection control, barrier precaution and preventive behaviors with all patients. In summary, the prevalence of HBV and HCV in our HD patients is still high. These data emphasize the need for stricter adherence to infection control, barrier precaution and preventive behaviors with all patients.